Showing results (551-560 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|February 24, 2026
Breaking barriers in women's pelvic health: claims-based economic analysis and healthcare utilization of an AI care program compared to usual careAna P Pereira, Andrea M Seet, Beatriz Domingues, et al.Journal of Medical Economics|February 28, 2026
Enhanced patient outcomes and improved budget impact from increased PFO diagnostic testing in cryptogenic stroke workup: a US hospital perspectiveJohn J Volpi, Giorgia Tiozzo, Jet Neervoort, et al.Journal of Medical Economics|March 6, 2026
Return on investment of national specific health guidance in Japan: an observational study using "Wellness-Star⋆" health insurance claims databaseTakuma Ueda, Akihiro Kakinuma, Masaru Kinugawa, et al.Journal of Medical Economics|March 17, 2026
The full value of mRNA seasonal influenza and endemic-stage COVID-19 combination vaccines: a taxonomyJ P Sevilla, Joseph S Knee, Daria Burnes, et al.Journal of Medical Economics|March 11, 2026
Real-world clinical, safety, and economic evaluation of infliximab biosimilar adoption for crohn's diseaseJihao Shi, Yipeng Pan, Qian Cao, et al.Journal of Medical Economics|April 13, 2026
Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancerGilberto de Lima Lopes, Harry Freeman, Emily Procter, et al.Journal of Medical Economics|April 8, 2026
Changes in drug price reduction trends during Japan's transition to an annualized revision environment: a comparative analysis using open data from the national claims databaseKoichi Tsuda, Asuka Suzuki, Yoshinori NakataJournal of Medical Economics|March 25, 2026
Epidemiology and economic burden of medically attended influenza and influenza-like illness in Germany, 2016-2019Anna C Meyer, Julian Witte, Manuel Batram, et al.Journal of Medical Economics|April 21, 2026
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United StatesStephen Williams, Sang Cho, Laura Morrison, et al.Journal of Medical Economics|April 21, 2026
Cost-utility of implantable tibial neuromodulation (Revi) versus conservative therapy for urgency urinary incontinence in adults: a US payer perspectiveCindy L Amundsen, Suzette E Sutherland, Sara M Lenherr, et al.Pageof 241